First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors.
Fernanda I Staquicini, Fenny Hf Tang, Vanessa de Oliveira...
https://pubmed.ncbi.nlm.nih.gov/40662373/Actively Recruiting
Led by MBrace Therapeutics · Updated on 2026-03-02
130
Participants Needed
17
Research Sites
17 weeks
Total Duration
Researchers are evaluating MBRC-101, an anti-EphA5 monomethyl auristatin E MMAE antibody drug conjugate, in patients with advanced metastatic solid tumors that have not responded to standard treatments. This first-in-human, open-label study includes Phase 1, Phase 1b, and Phase 2 phases to identify optimal dosing, assess safety, and evaluate preliminary clinical activity and efficacy in specific tumor types. The study is sponsored by MBrace Therapeutics and focuses on patients with no known beneficial standard care options. The study begins with Phase 1 dose escalation to find the maximum tolerated dose MTD and optimal biologically relevant doses OBRD of MBRC-101 in about 30 patients. Phase 1b involves dose expansion with approximately 60 patients across three cohorts with specific tumor types. After determining the recommended Phase 2 dose RP2D in Phase 1b, Phase 2 will enroll around 30 patients with a specific tumor type identified earlier to evaluate anti-tumor activity and safety. Safety is closely monitored throughout by a Safety Review Committee. Participants will undergo assessments including PET-CT, CT, and MRI scans evaluated by RECIST v1.1 criteria to measure response rates and disease control. Researchers will monitor treatment-emergent adverse events and dose-limiting toxicities over up to 24 months. Pharmacokinetic profiles and antibody incidence will be characterized. The study involves multiple treatment cycles with ongoing evaluations of overall response, progression-free survival, and overall survival to understand MBRC-101s effects and safety in this patient population.
CONDITIONS
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
K
Kellogg Parsons, MD, M.H.S.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
MBrace Therapeutics
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational MBRC-101 Antibody-Drug Conjugate | Current Guideline-Based Systemic Therapy (Standard of Care) |
|---|---|---|
| What it is | A novel antibody-drug conjugate targeting EphA5, conjugated to monomethyl auristatin E (MMAE), designed to deliver cytotoxic chemotherapy specifically to EphA5-expressing tumor cells. | Current guideline-directed systemic therapies are established regimens such as chemotherapy, targeted therapy, immunotherapy, or combinations based on tumor type and molecular subtype for advanced solid tumors. |
| Primary use | Investigated for safety, pharmacokinetics, dose-limiting toxicities, and preliminary antitumor activity in patients with advanced solid tumors unresponsive to available therapies. | Used as disease-directed therapy for advanced solid tumors, sometimes with curative or disease-stabilizing intent, depending on the specific regimen and tumor type. |
| Evidence status | MBRC-101 is in early clinical evaluation (Phase 1/2), with no mature clinical efficacy data in humans. Preclinical studies show activity against EphA5-expressing tumors. | Systemic therapies are supported by robust clinical evidence for efficacy in advanced solid tumors at earlier lines, improving survival and symptom control in eligible patients at each respective disease stage and subtype. |
| Important limitations | Uncertainties include unknown human safety profile, limited efficacy evidence beyond preclinical studies, and potential for cohort-specific restrictions as dose escalation and expansion progress. Enrolled patients are heavily pretreated and may have limited response. | Guideline-based therapies have limited utility for patients who are refractory, ineligible, or at the end of therapeutic lines. Toxicity (hematologic, hepatic, neuropathy) may restrict use, and evidence supports each regimen only within its approved indication and disease stage. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months depending on treatment phase and patient response
Participants receive MBRC-101, an anti-EphA5 antibody drug conjugate, to evaluate safety and preliminary efficacy. Treatment includes dose escalation in Phase 1, dose expansion in Phase 1b, and further treatment at the recommended dose in Phase 2.
Repeated visits for treatment cycles, with frequency determined by study phase and dosing regimen
Duration - Up to 24 months
Participants are monitored for safety and treatment outcomes after completing treatment cycles or discontinuation.
Visits scheduled at regular intervals for safety and efficacy assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Fernanda I Staquicini, Fenny Hf Tang, Vanessa de Oliveira...
https://pubmed.ncbi.nlm.nih.gov/40662373/MBrace Therapeutics
Lead Sponsor